AbbVie (ABBV) announced it received a Complete Response Letter from the FDA regarding the Biologics License Application for trenibotulinumtoxinE, a botulinum neurotoxin serotype E with a rapid onset of effect and short duration. The FDA requested additional information about manufacturing processes.
The company noted that the CRL does not identify any safety or efficacy concerns for TrenibotE, and does not request additional clinical studies. AbbVie expects to submit a thorough response in the coming months.
At last close, AbbVie shares were trading at $200.95, up 0.22%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.